GLP-1 coverage in Connecticut

Medicaid coverage of GLP-1s for obesity is optional for states under a long-standing statutory exception. Connecticut has exercised that discretion in a specific way.

Connecticut Medicaid covers weight-loss drugs but not GLP-1s.

Connecticut appears on KFF’s list of states covering one or more weight-loss drugs with no GLP-1 coverage. Ask about the specific drug by name when you check. Everything below is sourced — we are not going to tell you what a Connecticut clinic charges, because every provider we track is 50-state telehealth and prices the same wherever you live. What actually differs by state is coverage, and that is what this page is about.

Why Connecticut is different

Connecticut is a Northeast state with one of the lower regional obesity prevalences at 30.3%, and it covers a weight-loss drug without covering any GLP-1. It is a useful reminder that a wealthier state with a well-regarded Medicaid programme is not automatically a more generous one on this specific question.

Medicaid and GLP-1s in Connecticut

Coverage for obesity is optional for states — the national picture is on our coverage index. Here is where Connecticut sits.

If you are on Medicaid in Connecticut

What to do in Connecticut: Get the formulary position in writing for the named drug before you assume the weight-loss benefit applies to it.

Coverage for type 2 diabetes, cardiovascular disease and sleep apnea is mandatory everywhere, so a refusal framed around weight loss is not the end of it — and on Medicare, the $50 programme starts 1 July 2026 regardless of which state you are in.